Type of adverse event: infection · people with CKD
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
1 finding from 1 review
Numbers of non‐dialysis patients needing to commence dialysis · people with CKD
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
1 finding from 1 review
Blood transfusion · people with CKD
Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).
1 finding from 1 review
increase in the amount of egg that can be tolerated · children with egg allergy
Oral and sublingual immunotherapy may leads to higher increase in the amount of egg that could be tolerated compared with no therapy (low certainty).
1 finding from 1 review
Complete recovery · children with egg allergy
Oral and sublingual immunotherapy may leads to higher complete recovery compared with no therapy (low certainty).
1 finding from 1 review
Numbers of children with serious adverse events · children with egg allergy
1 finding from 1 review
Number of children with mild‐to‐severe adverse events · children with egg allergy
Oral and sublingual immunotherapy may leads to higher number of children with mild‐to‐severe adverse events compared with no therapy (low certainty).
1 finding from 1 review
All strokes and systemic embolic events · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in all strokes and systemic embolic events compared with warfarin (moderate certainty).
1 finding from 1 review
Major bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).
1 finding from 1 review
Myocardial infarction · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in myocardial infarction compared with warfarin; GRADE not reported.
1 finding from 1 review
Minor bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in minor bleeding compared with warfarin (low certainty).
1 finding from 1 review
Gastrointestinal bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in gastrointestinal bleeding compared with warfarin (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) probably leads to lower intracranial haemorrhage compared with warfarin (moderate certainty).
1 finding from 1 review
All‐cause mortality · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).
1 finding from 1 review
Change in disability score · non‐ambulatory children and adolescents with SMA types II and III
4 findings from 1 review
no estimate extracted
1 study · 160 participants
Very low
no estimate extracted
1 study · 160 participants
Very low
RR 1.43
1 study · 160 participants
Very low
Show 1 more finding
Muscle strength · non‐ambulatory children and adolescents with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acquiring the ability to stand or walk · non‐ambulatory children and adolescents with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III
1 finding from 1 review
Change in pulmonary function · non‐ambulatory children and adolescents with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children and adolescents with SMA types II and III
1 finding from 1 review